| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Nangibotide | LR-12 | Phase 2 Clinical | Inotrem | Coronavirus Disease 2019 (COVID-19); Shock, Septic | Details |
| ABBV-8736 | ABBV-8736 | Phase 2 Clinical | Abbvie Inc | Crohn Disease; Inflammatory Bowel Diseases | Details |
| TREM-1 antibody (Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Autoimmune Diseases | Details | |
| CEL383 | CEL-383 | Phase 1 Clinical | Celsius Therapeutics Inc | Inflammatory Bowel Diseases | Details |
| TREM 1 antibody(Boehringer Ingelheim International Gmbh) | TREM 1 antibody(Boehringer Ingelheim International Gmbh) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Immune System Diseases | Details |
| PY-159 | PY-159 | Phase 1 Clinical | Centre for the Commercialization of Antibodies and Biologics | Neoplasms; Solid tumours | Details |